evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract
17784,GENE_SUMMARY,,CD79B encodes a component the B-cell antigen receptor that functions in signaling important for the maturation and survival of B-cells. CD79B is frequently mutated in diffuse large B-cell lymphoma.,,2017-01-09,,974,CD79B,CD79b molecule,False,ENST00000392795,NM_001039933.1,AGM6,IGB,B29,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17785,GENE_BACKGROUND,,"CD79B is a surface immunoglobulin that forms a complex with CD79A to form a component of the B-cell receptor (BCR) (PMID:1439759). The CD79 (Iga/Igb) complex is important for signaling from the BCR to support maturation and survival of B-cells throughout development (PMID:15186779, 8602530). The cytoplasmic portion of CD79B contains immunoreceptor tyrosine-based activation motif (ITAM) domains that become phosphorylated by SRC proto-oncogene family protein kinases. These regions serve as docking sites for signaling complex formation with kinases such as SYK (spleen tyrosine kinase) and for signal regulation (PMID: 17114463, 20940318, 22078222). Activating mutations of CD79B have been identified in diffuse large B-cell lymphoma, particularly the activated B-cell-like subtype (PMID: 20054396) suggesting that CD79B acts as an oncogene. CD79B mutations result in increased surface BCR expression, reduced BCR internalization and dampening of LYN (Lyn proto-oncogene) kinase feedback inhibition, thus resulting in increased BCR signaling. Somatic mutation in the protein's ITAM domain have also been identified and shown to affect signaling (PMID: 20054396). Germline CD79B mutation leads to agammaglobulinemia, a severe immunodeficiency syndrome with B-cell dysfunction (PMID: 17709424). Antibody-drug conjugates targeting CD79B and inhibitors targeting SRC activity, such as dasatinib, can reduce BCR signaling (PMID: 17374736, 20054396, 25925619, 28009435).",,2017-09-12,,974,CD79B,CD79b molecule,False,ENST00000392795,NM_001039933.1,AGM6,IGB,B29,False,17114463,Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation.,"Journal of immunology (Baltimore, Md. : 1950)",2017-12-01T20:06:00,177,11,7913-22,Fuentes-Panan√° EM et al,,,2017-12-01T19:50:00,,1439759,The B cell antigen receptor complex: association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors.,"Science (New York, N.Y.)",0001-10-02,258,5079,123-6,Clark MR et al,,,0001-10-02,,17374736,Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.,Blood,2018-07-15T20:07:00,110,2,616-23,Polson AG et al,,,0001-07-15,,20940318,Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor.,Proceedings of the National Academy of Sciences of the United States of America,2018-10-26T20:10:00,107,43,18563-8,Heizmann B et al,doi: 10.1073/pnas.1009048107,,0001-10-26,,20054396,Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.,Nature,2018-01-07T20:10:00,463,7277,88-92,Davis RE et al,doi: 10.1038/nature08638,,0001-01-07,,28009435,Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.,British journal of pharmacology,2018-04-01T20:17:00,174,8,628-640,Fuh FK et al,doi: 10.1111/bph.13697,,2018-04-01T06:40:00,,17709424,Mutations of the Igbeta gene cause agammaglobulinemia in man.,The Journal of experimental medicine,2018-09-03T20:07:00,204,9,2047-51,Ferrari S et al,,,0001-09-03,,25925619,Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.,The Lancet. Oncology,2018-06-01T20:15:00,16,6,704-15,Palanca-Wessels MC et al,doi: 10.1016/S1470-2045(15)70128-2,,0001-06-01,,8602530,Regulation of an early developmental checkpoint in the B cell pathway by Ig beta.,"Science (New York, N.Y.)",0001-04-19,272,5260,411-4,Gong S et al,,,0001-04-19,,22078222,Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.,Immunity,2017-11-23T20:11:00,35,5,746-56,O'Neill SK et al,doi: 10.1016/j.immuni.2011.10.011,,0001-11-23,,15186779,Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.,Cell,2018-06-11T20:04:00,117,6,787-800,Kraus M et al,,,2018-06-11T08:00:00,
